Preoperative Vaginal Dinoprostone Prior to Abdominal Myomectomy

NCT ID: NCT04080375

Last Updated: 2019-09-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-10

Study Completion Date

2019-12-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to compare the effectiveness of vaginal dinoprostone 3 mg versus placebo before myomectomy to decrease blood loss during and after the operation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myomectomy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

dinoprostone 3 mg

patients will take 1 tablet of vaginal dinoprostone 1 hour before the surgery

Group Type EXPERIMENTAL

Dinoprostone 3 mg

Intervention Type DRUG

the patient will take one vaginal tablet of 3 mg dinoprostone 1 hour before surgery

placebo

patients will take 1 tablet of placebo 1 hour before the surgery

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

the patient will take one vaginal tablet of placebo 1 hour before surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dinoprostone 3 mg

the patient will take one vaginal tablet of 3 mg dinoprostone 1 hour before surgery

Intervention Type DRUG

placebo

the patient will take one vaginal tablet of placebo 1 hour before surgery

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Patients presenting for abdominal myomectomy with documented uterine fibroids on pelvic imaging

* Age ≥ 18 years and ≤ 50 years
* Pre-operative hemoglobin \>8 g/dl
* Ability to understand and the willingness to sign a written informed consent.
* Admissible medical/surgical history
* Five or less symptomatic uterine myomas
* All myomas are subserous or intramural.
* Uterine size less than 24 weeks pregnancy

Exclusion Criteria

* • Patients who have had a prior abdominal myomectomy

* Post-menopausal women
* Patients with known bleeding/clotting disorders
* Patients with a history of gynecologic malignancy
* Hypertension.
* Cardiac and Pulmonary diseases.
* Obesity (body mass index \> 30 kg/m2).
* History of allergic reactions attributed to misoprostol
* Cases that will require intraoperative conversion of myomectomy to hysterectomy.
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ahmed Samy aly ashour

assistant professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

AHMED SAMY

Role: PRINCIPAL_INVESTIGATOR

Cairo University

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

AHMED SAMY

Role: CONTACT

+201100681167

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

dinoprostone myomectomy

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.